Y-mAbs Therapeutics, Inc. (YMAB) Stock Price, News, Quote & History - Yahoo Finance (2024)

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(zt)}else s.style.display="block"},f=function(){d.refreshPanel().then(h).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){xe(c)||u()})),c&&(f(),setInterval((function(){f()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var m=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(eo=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===m&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Gt)),notifLabel:document.querySelector(".".concat(Wt))};to(e,n)}))}()}};

NasdaqGS - Delayed Quote • USD

Compare

12.00 +0.25 (+2.13%)

At close: June 21 at 4:00 PM EDT

12.00 -0.00 (-0.01%)

After hours: June 21 at 4:16 PM EDT

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for YMAB

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

• Previous Close 11.75
• Open 11.82
• Bid 11.92 x 100
• Ask 12.07 x 100
• Day's Range 11.69 - 12.02
• 52 Week Range 4.60 - 20.90
• Volume 345,692
• Avg. Volume 355,520
• Market Cap (intraday) 526.591M
• Beta (5Y Monthly) 0.68
• PE Ratio (TTM) --
• EPS (TTM) -0.49
• Earnings Date Aug 8, 2024 - Aug 12, 2024
• Forward Dividend & Yield --
• Ex-Dividend Date --
• 1y Target Est 21.14

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

www.ymabs.com

100

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Y-mAbs Therapeutics, Inc.

Recent News: YMAB

View More

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Tender Offer/Acquisition Reports

Offering Registrations

See Also

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma | Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics Inc (YMAB) Stock Price & News - Google FinanceY-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA | Y-mAbs Therapeutics, Inc.

View More

Performance Overview: YMAB

Trailing total returns as of 6/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

YMAB

75.95%

S&P 500

14.57%

1-Year Return

YMAB

61.07%

S&P 500

24.52%

3-Year Return

YMAB

66.87%

S&P 500

31.16%

5-Year Return

YMAB

44.11%

S&P 500

84.98%

Compare To: YMAB

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

YMABY-mAbs Therapeutics, Inc.

12.00

+2.13%

Mkt Cap 526.591M

Industry Biotechnology

BCYCBicycle Therapeutics plc

20.53

+1.53%

Mkt Cap 1.414B

Industry Biotechnology

REPLReplimune Group, Inc.

8.50

+8.01%

Mkt Cap 522.028M

Industry Biotechnology

IKNAIkena Oncology, Inc.

1.7200

+3.61%

Mkt Cap 83.004M

Industry Biotechnology

DAWNDay One Biopharmaceuticals, Inc.

13.68

+4.27%

Mkt Cap 1.195B

Industry Biotechnology

SRRKScholar Rock Holding Corporation

8.45

+1.81%

Mkt Cap 673.922M

Industry Biotechnology

ELEVElevation Oncology, Inc.

2.5600

-7.41%

Mkt Cap 139.874M

Industry Biotechnology

ONCTOncternal Therapeutics, Inc.

8.18

+2.00%

Mkt Cap 24.21M

Industry Biotechnology

NUVBNuvation Bio Inc.

3.0500

+0.66%

Mkt Cap 756.922M

Industry Biotechnology

SWTXSpringWorks Therapeutics, Inc.

36.12

-0.22%

Mkt Cap 2.676B

Industry Biotechnology

PHATPhathom Pharmaceuticals, Inc.

11.08

-6.18%

Mkt Cap 648.57M

Industry Biotechnology

Statistics: YMAB

View More

Valuation Measures

Annual

As of 6/21/2024

• Market Cap

  527.03M

• Enterprise Value

  452.46M

• Trailing P/E

  --

• Forward P/E

  --

• PEG Ratio (5yr expected)

  --

• Price/Sales (ttm)

  6.21

• Price/Book (mrq)

  5.31

• Enterprise Value/Revenue

  5.35

• Enterprise Value/EBITDA

  --

Financial Highlights

Profitability and Income Statement

• Profit Margin

  -25.64%

• Return on Assets (ttm)

  -12.02%

• Return on Equity (ttm)

  -20.93%

• Revenue (ttm)

  84.5M

• Net Income Avi to Common (ttm)

  -21.67M

• Diluted EPS (ttm)

  -0.49

Balance Sheet and Cash Flow

• Total Cash (mrq)

  75.75M

• Total Debt/Equity (mrq)

  1.19%

• Levered Free Cash Flow (ttm)

  -11.46M

View More

Research Analysis: YMAB

View More

View More

Company Insights: YMAB

Research Reports: YMAB

View More

View More

People Also Watch

REPL Replimune Group, Inc.

8.50

+8.01%

SRRK Scholar Rock Holding Corporation

8.45

+1.81%

STOK Stoke Therapeutics, Inc.

14.23

-3.59%

CRNX Crinetics Pharmaceuticals, Inc.

45.58

+3.10%

PHAT Phathom Pharmaceuticals, Inc.

11.08

-6.18%

STRO Sutro Biopharma, Inc.

3.2300

-1.52%

MGTX MeiraGTx Holdings plc

4.4000

+2.09%

ORIC ORIC Pharmaceuticals, Inc.

7.23

+3.14%

KNSA Kiniksa Pharmaceuticals, Ltd.

18.61

+3.50%

IGMS IGM Biosciences, Inc.

7.30

+12.14%

VRCA Verrica Pharmaceuticals Inc.

7.45

+3.33%

ZNTL Zentalis Pharmaceuticals, Inc.

4.7500

-9.52%

MRSN Mersana Therapeutics, Inc.

2.1300

+4.41%

SWTX SpringWorks Therapeutics, Inc.

36.12

-0.22%

AVRO AVROBIO, Inc.

1.4000

-1.41%

RYTM Rhythm Pharmaceuticals, Inc.

41.87

+2.93%